Evidence map›Paper›PMID 18704411›Full record

ArticleCancer immunology, immunotherapy : CII2009

Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes.

Chin-Hsuan Hsieh, Ya-Jan Hsu, Chien-Chung Chang, Hsin-Chun Liu, Kun-Lung Chuang, Cheng-Keng Chuang, See-Tong Pang, Kenichiro Hasumi, Soldano Ferrone, Shuen-Kuei Liao

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Therapeutic cancer vaccines: current status and moving forward.Journal of the National Cancer Institute · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Chin-Hsuan HsiehGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Ya-Jan Hsu
Chien-Chung Chang
Hsin-Chun Liu
Kun-Lung Chuang
Cheng-Keng Chuang
See-Tong Pang
Kenichiro Hasumi
Soldano Ferrone
Shuen-Kuei Liao
Chang Gung Memorial Hospital · TWChang Gung University · TWNational Tsing Hua University · TWUPMC Hillman Cancer Center · US

Funding

HLA CLASS I PEPTIDE COMPLEX ADNORMALITIES IN MELANOMAR01CA067108 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FERRONE, SOLDANO · 1996 to 2004
$1.5M
Antigen processing and HLA-peptide complexes in head and neck cancerR01CA110249 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FERRONE, SOLDANO · 2006 to 2010
$1.5M
NCI NIH HHS R01 CA067108NCI NIH HHS R01 CA110249NCI NIH HHS R01CA110249NCI NIH HHS R01CA67108
6 · The paper itself

Abstract

In renal cell carcinoma (RCC), HLA class I downregulation has been found in about 40% of the lesions examined. Since only scanty information is available about the molecular basis of these defects, we have investigated the mechanism(s) underlying HLA class I antigen downregulation or loss in six RCC cell lines. Five of them express HLA class I antigens although at various levels; on the other hand, HLA class I antigens are not detectable on the remaining cell line, the RCC52 cell line, belonging to a sarcomatoid subtype, even following incubation with IFN-gamma. beta(2)-microglobulin (beta(2) m) was not detected in RCC52 cells. Surprisingly, RCC52 cells harbor two mutations in the beta ( 2 ) m genes in exon 1: a single G deletion (delG) in codon 6, which introduces a premature stop at codon 7, and a CT dinucleotide deletion (delCT), which leads to a premature stop at codon 55. Analysis of eight clonal sublines isolated from the RCC52 cell line showed that the two beta ( 2 ) m gene mutations are carried separately by RCC52 cell subpopulations. The delG/delCT double mutations were detected in two sublines with a fibroblast-like morphology, while the delCT mutation was detected in the remaining six sublines with an epithelial cell morphology. Furthermore, loss of heterozygosity (LOH) of the beta ( 2 ) m gene at STR D15S-209 was found only in the epithelioid subpopulation, indicating loss of one copy of chromosome 15. Immunostaining results of the tumor lesion from which the cell line RCC52 was originated were consistent with the phenotyping/molecular findings of the cultured cells. This is the first example of the coexistence of distinct beta ( 2 ) m defects in two different tumor subpopulations of a RCC, where loss of one copy of chromosome 15 occurs in one of the subpopulations with total HLA class I antigen loss.

Indexed as

Gene Expression Regulation, NeoplasticGenes, MHC Class IMutationAnimalsbeta 2-MicroglobulinCarcinomaCell Line, TumorEpithelial CellsHLA AntigensHumansInterferon-gammaKidney NeoplasmsLoss of HeterozygosityMiceSarcomabeta 2-MicroglobulinHLA AntigensInterferon-gamma

Identifiers

PMID18704411
PMCPMC2793116
OpenAlexW1991396576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.